MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejmech.2026.119274

Медицинская библиотека · European journal of medicinal chemistry · 2026

Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy.

He Zhiyue, Zhang Yingying, Zhan Shiping, Cao Tian, Bai Wanru, Zhou Bozhi, Yu Jie, Zeng Huiying, Zhou Jingyi, Tian Fuyun, Chen Xiaoyan, Zhang Sulin, Zheng Mingyue, Wu Xiaowei

СтатьяПеревод в очереди

Аннотация

In this study, new imidazo[1,2-a]pyrazine derivative 15 (YS3074) and pyrazine derivative 17 (YS3375) are identified and optimized as potent and selective ENPP1 inhibitors. Compounds 15 and 17 both exhibited high potency and selectivity toward ENPP1 (IC50 = 4.23 nM and 19.4 nM, respectively) with negligible ENPP2 inhibition (>10 μM) and weak ENPP3 inhibition (>3 μM). Both enhanced cGAMP-induced expression of STING pathway genes (IFNB1, CXCL10, IL6) in a concentration-dependent manner without cytotoxicity, producing stronger and more sustained activation than MV-658. This effect, dependent on the cGAMP-STING axis, was attributed to inhibition of ENPP1-mediated cGAMP hydrolysis. Additionally, compounds 15 and 17 showed no inhibition of the hERG channel (IC50 > 30 μM), indicating a favorable cardiac safety profile. In the CT-26 colorectal cancer model, compounds 15 and 17, administered at 40 mg/kg in combination with an anti-PD-1 antibody, achieved superior tumor growth inhibition (TGI: 73% and 67%, respectively), significantly prolonged survival, and were well tolerated with no observable body weight loss. These results establish 15 and 17 as promising ENPP1 inhibitors with favorable safety profiles, supporting their potential in combination cancer immunotherapy.

Для цитирования: He Zhiyue, Zhang Yingying, Zhan Shiping, Cao Tian, Bai Wanru, Zhou Bozhi, Yu Jie, Zeng Huiying, Zhou Jingyi, Tian Fuyun, Chen Xiaoyan, Zhang Sulin, Zheng Mingyue, Wu Xiaowei. Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy.. European journal of medicinal chemistry. 2026. DOI: 10.1016/j.ejmech.2026.119274.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.